Wells Fargo
RANI icon

Wells Fargo’s Rani Therapeutics RANI Stock Holding History

Wells Fargo’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-103
Closed -$320 – 7354
2024
Q1 		$320 Buy
103
+1
+1% +$3 ﹤0.01% 6385
2023
Q4 		$339 Buy
102
+8
+9% +$18 ﹤0.01% 6471
2023
Q3 		$204 Buy
94
+17
+22% +$65 ﹤0.01% 6580
2023
Q2 		$317 Buy
77
+5
+7% +$23 ﹤0.01% 6572
2023
Q1 		$372 Buy
72
+2
+3% +$12 ﹤0.01% 6620
2022
Q4 		$413 Buy
70
+2
+3% +$15 ﹤0.01% 6436
2022
Q3 		$1K Sell
68
-12,462
-99% -$132K ﹤0.01% 6436
2022
Q2 		$129K Buy
12,530
+57
+0.5% +$654 ﹤0.01% 4500
2022
Q1 		$168K Buy
12,473
+12,472
+1,247,200% +$207K ﹤0.01% 5082
2021
Q4 		$0 Sell
1
-39
-98% -$886 ﹤0.01% 7691
2021
Q3 		$1K Buy
+40
New +$692 ﹤0.01% 6775

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo's RANI Position: Q2 2024 in Review

Wells Fargo sold out of Rani Therapeutics (RANI) in Q2 2024, closing a stake of 103 shares — an estimated $320 sold.

Wells Fargo first reported a position in RANI in Q3 2021 and held it in 11 quarters. The position peaked at $168K in Q1 2022. 34 funds tracked by Wall St. Rank hold RANI as of Q2 2024.

  • Wells Fargo reported no remaining Rani Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 103 Rani Therapeutics shares in Q2 2024, an estimated $320.
  • Wells Fargo first reported a position in Rani Therapeutics in Q3 2021 and held it in 11 quarters.
  • Wells Fargo's Rani Therapeutics position peaked at $168K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.